Zetagen Therapeutics, Inc. Awarded $300,000 USD Grant from the National Cancer Institute (NCI) for Phase I Study of Novel, Adjuvant Implant for Post-Metastatic Skeletal Lesions

• U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
• Grant will allow for Phase I validation study of ZetaMet™ (Zeta-BC-003) via a proprietary, drug eluting implant
• Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions

September 5, 2018– (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today its award of a $300,000 (USD) grant from the National Cancer Institute of the National Institutes of Health (NIH). The grant will be used for a Phase I validation study of the Company’s proprietary, drug-eluding implant called ZetaMet™ (Zeta-BC-003). ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, inductive biologic being developed to suspend tumor growth and regrow bone.

“We are pleased that the National Cancer Institute, through this award, has recognized the potential ZetaMet™ (Zeta-BC-003) may hold for treating metastatic bone lesions,” said Nikhil Thakur, MD, CMO of Zetagen Therapeutics, Inc. “Osteolytic metastases are among the most challenging of cancers to treat as they both destroy bone and cause debilitating pain in patients.”

The grant is part of the Small Business Innovation Research Program (SBIR), a three-phase award system created by the Federal Government for small businesses to engage in research and development that has the potential for commercialization and public benefit. Zetagen exclusively licensed its platform technology from the State University of New York in 2016. The Company’s Phase I validation study will begin in Q4 2018.